HK Stock Market Move | LAEKNA-B (02105) rises by over 9%, breast cancer candidate drug LAE002 wins a large single-day order of 20.45 billion BD.

LAEKNA-B(02105) rose more than 9%, reaching a 6.71% increase as of the publication, and closing at 14.32 Hong Kong dollars, with a transaction value of 92.6587 million Hong Kong dollars. On the news front, on November 12, Linkai Pharmaceuticals granted Lu Pharmaceuticals the regional rights to breast cancer candidate new drug LAE002 (afuresertib) in China, with a total transaction amount of 2.045 billion yuan. Additionally, Linkai Pharmaceuticals also has the right to receive a sales gradient of more than 10 to 20 percent. LAE002 is one of the two AKT inhibitors targeting breast cancer and prostate cancer in late-stage clinical development globally. Public information shows that LAE002 is a potent AKT inhibitor that can inhibit all three AKT subtypes (AKT1, AKT2, and AKT3). LAE002 for HR+/HER2- breast cancer is second only to AstraZeneca's Capivasertib globally. According to brokerage research reports, the peak sales of LAE002 in China are estimated to be around 2 billion yuan, and global sales can be referenced to Capivasertib. Capivasertib is expected to have sales of 700-800 million US dollars this year, with peak sales estimated at 1-2 billion US dollars.